facebook button GX41563: Genentech, Inc.: Prospective Clinicogenomic Program (PCG)
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

GX41563: Genentech, Inc.: Prospective Clinicogenomic Program (PCG)

Sponsor: Genentech, Inc.

A Multicenter, Low-Interventional Study to Evaluate the Feasibility of a Prospective Clinicogenomic Program for participants with Metastatic Non-small Cell Lung Cancer (mNSCLC) or Extensive-stage Small-cell Lung Cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.

For more information please contact the clinical research department: 631-675-5075